Polymer conjugates of Box-A of HMGB1 and Box-A variants of HMGB1
The present invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A. Further, the invention relates to novel polymer conjugates of polypeptide variants of the HMGB1 high affinity binding domain Box-A (HMGB1 Box-A). Moreover, the present invention concerns the use of said polymer conjugates of polypeptide molecules of HMGB1 Box-A to diagnose, prevent, alleviate and/or treat pathologies associated with extracellular HMGB1 and/or associated with an increased expression of RAGE.
1. A polymer conjugate comprising a polypeptide variant of the human and/or non human HMGB1 high affinity binding domain Box-A (HMGB1 Box-A) or of a biologically active fragment of HMGB1 Box-A, whereby the amino acid sequence of said polypeptide variant differs from the amino acid sequence of the wild type HMGB1 Box-A by the mutation of one or more single amino acid, wherein the polypeptide variant of the human HMGB1 Box-A is selected from the group consisting of amino acid sequences defined by SEQ ID NO: 35, 43, 57, 64, 69, and 104, and at least one linear or branched polymer moiety selected from the group consisting of polyalkylene glycol, polyalkylene oxide, polyacrylic acid, polyacrylate, polyacrylamide, N-alkyl polyacrylate derivatives, polymethacrylic acid, polymethacrylate, polyethylacrylic acid, polyethylacrylate, polyvinylpyrrolidone, poly (vinylalcohol), polyglycolic acid, polyactic acid, poly(lactic-co-glycolic) acid, dextran, chitosan and polyaminoacid.
2. The polymer conjugate of claim 1 , wherein the amino acid sequence of said polypeptide variant of the human HMGB1 Box-A is defined by SEQ ID NO:64.
3. The polymer conjugate of claim 1 , wherein the polymer is a linear or branched polymer moeity selected from polyethylene glycol (PEG) or methoxy polyethylene glycol (m-PEG).
4. A composition comprising the polymer conjugate of claim 1 as an active agent and a pharmaceutically acceptable carrier, adjuvant, diluent or additive.
5. The composition of claim 4 , wherein the polymer conjugate is in combination with at least one further agent.
6. A medical device comprising surfaces, wherein the conjugate of claim 1 is reversibly immobilized on at least one of said surfaces.